ArticleInternational journal of women's health2026
Association Between Peripheral Blood Lymphocyte Count and HER2 Status in Breast Cancer: A Retrospective Study.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Overexpression of human epidermal growth factor receptor 2 (HER2) in breast cancer is associated with aggressive tumor biology and a distinct immune microenvironment. Although the absolute lymphocyte count (ALC) in peripheral blood is widely used as a routine indicator of systemic immune function, its relationship with HER2 status remains insufficiently explored. Methods: This retrospective study investigated the association between pretreatment peripheral ALC and HER2 status in a cohort of breast cancer patients. Multivariate logistic regression, random forest modeling, and restricted cubic spline (RCS) analyses were employed to assess this relationship. Subgroup analyses were conducted across major clinical and pathological variables to evaluate their robustness. In parallel, tumor immune infiltration profiles were analyzed using the TIMER 2.0 platform. Results: A robust and consistent inverse association was observed between ALC and HER2-positive status across all analytical approaches. In fully adjusted logistic regression models, higher ALC was independently associated with lower odds of HER2 positivity (OR= 0.53, 95% CI: 0.37-0.77, P<0.001), with consistent effects across all examined subgroups. Further immune profiling using the TIMER 2.0 platform demonstrated that ERBB2 (HER2) expression was negatively correlated with the infiltration of key anti-tumor lymphocytes, including CD8⁺ T cells, activated memory CD4⁺ T cells, and natural killer (NK) cells, while showing relative enrichment of immature B cells and non-regulatory CD4⁺ T cells. Collectively, these findings suggest that HER2-overexpressing tumors are associated with concurrent systemic immune alterations and a locally suppressed tumor immune microenvironment. Conclusion: Peripheral blood ALC levels are negatively correlated with HER2 expression in breast cancer. Given its accessibility and cost-effectiveness, ALC may serve as a complementary systemic immune indicator for contextual assessment of HER2-related immune characteristics and immune heterogeneity at the population level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.